ALX Oncology Holdings Inc. has amended its 2025 Inducement Equity Incentive Plan, increasing the total number of shares reserved for issuance under the plan by 1,300,000, bringing the aggregate total to 2,800,000 shares. The plan allows for the grant of equity-based awards, such as nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, and performance shares, to individuals entering employment with the company who were not previously employees or non-employee directors. The terms of the Inducement Plan are substantially similar to the company’s Amended and Restated 2020 Equity Incentive Plan, including the treatment of equity awards in the event of a merger or change in control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-018094), on January 21, 2026, and is solely responsible for the information contained therein.